No Data
No Data
Guizhou Sanli Pharmaceutical Plans Up to 120-Million-Yuan Share Buyback
Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH): The controlling shareholder voluntarily promises not to reduce its shareholding in the company within 18 months.
On September 12, Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH) announced that, based on the confidence in the company's future prospects and long-term value, and to enhance the confidence of investors and effectively protect the rights and interests of investors and the stability of the capital markets, Mr. Zhang Hai, the controlling shareholder and actual controller of the company, voluntarily pledged not to actively reduce his directly held shares of the company within 18 months from September 13, 2024 (i.e. from September 13, 2024 to March 12, 2026) in any way. As of the date of this announcement, Mr. Zhang Hai holds 167,668,440 shares of the company, accounting for
guizhou sanli pharmaceutical co.,ltd. (603439.SH): plans to invest 80 million yuan to 0.12 billion yuan to repurchase shares.
Guizhou Sanli (603439.SH) announced on September 12th that the company's shares repurchase plan will be used for the implementation of employee shareholding plan or stock-based incentive plan. The amount of shares repurchased will not be less than RMB 80 million (inclusive), and will not exceed RMB 120 million (inclusive). The repurchase price of shares will not exceed RMB 17.85 per share (inclusive).
Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH): Wang Huiying has cumulatively reduced her shareholding by 2.9648%.
Gelonghui, September 6th, Guizhou Sanli (603439.SH) announced that on September 5, 2024, the company received the "Early Termination of Shareholding Reduction Plan and Notification of Shareholding Reduction Results" from the controlling shareholder and its concerted action person. Ms. Wang Huiying has reduced her shareholding by a total of 12,150,000 shares through block trading and centralized auction trading from September 3, 2024 to September 5, 2024, accounting for 2.9648% of the total share capital of the company. Mr. Zhang Hai did not reduce his shareholding during this period. Based on the confidence in the company's sustained and stable development and the reasonable determination of the company's value, the controlling shareholder and its concerted action
Guizhou Sanli Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
2024 Semi-Annual Report Summary
No Data
No Data